Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital

Published:2017-11-09 Issue:7 Volume:59 Page:1586-1595
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gleeson Mary¹,Peckitt Clare¹,Cunningham David¹,Gibb Adam²,Hawkes Eliza A.³⁴,Back Morgan²,Yasar Binnaz²,Foley Kate²,Lee Rebecca²,Dash Joanna²,Johnson Hannah²,O’Hara Catherine²,Wotherspoon Andrew¹,Attygalle Ayoma¹,Menasce Lia²,Shenjere Patrick²,Potter Mike¹,Ethell Mark E.¹,Dearden Claire¹,Radford John²,Chau Ian¹,Linton Kim²

Affiliation:

1. The Royal Marsden Hospital, London and Surrey, UK;

2. The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK;

3. Department of Oncology and Clinical Haematology, Austin Health, Heidelberg, Australia;

4. Eastern Health, Melbourne, Australia

Funder

National Institute for Health Research (NIHR) Royal Marsden Hospital/Institute of Cancer Research Biomedical Research Centre, London, UK

Amgen

AstraZeneca

Bayer

Celgene

Merrimack

Medimmune

Merck Serono

Sanofi

Bristol-Myers Squibb

Merck KgA

Janssen-Cilag

Sanofi Oncology

Merck-Serono

Novartis

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1393671

Reference25 articles.

1. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

2. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

3. Revised Response Criteria for Malignant Lymphoma

4. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

5. Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis;Bone Marrow Transplantation;2024-03-05

2. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin;PharmacoEconomics - Open;2022-09-04

3. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-03

4. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort;Advances in Therapy;2021-05-26

5. Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma;Chinese Journal of Cancer Research;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3